Drugs / Episcleral Dexamethasone
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT04120311 | Sep 2019 → Sep 2024 | central serous chorioretinopathy, hyalitis, macular retinal edema, occlusion of tributary of retinal vein +1 | Targeted Therapy Technologies, LLC | Unknown | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Episcleral Dexamethasone | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04120311 ↗ |
| Route | Other | “Delivered Via Episcleral Reservoir” NCT04120311 ↗ |